{"id":"assay_pik3cg_0001","dataset":"BindingDB","target":"PIK3CG","uniprot_id":"Q15858","assay_id":"BDB:123456","compound_id":"CMPD-001","smiles":"CCN1CCC(NC(=O)c2ccc(Cl)cc2)CC1","text":"BindingDB assay [BDB:123456]. Target: PIK3CG (Q15858). Compound CMPD-001. IC50 = 85 nM (mean of 3). Cell line: CHO. Buffer: phosphate. Temp: 25 °C. Notes: ATP-competitive inhibitor."}
{"id":"assay_egfr_0001","dataset":"BindingDB","target":"EGFR","uniprot_id":"P00533","assay_id":"BDB:223344","compound_id":"CMPD-002","smiles":"COc1ccc2nc(N)nc(N3CCN(CC3)C)c2c1","text":"BindingDB assay [BDB:223344]. Target: EGFR (P00533). Compound CMPD-002. IC50 = 12 nM (n=2). Assay format: kinase biochemical. Buffer: HEPES. Temp: 23 °C."}
{"id":"herg_pred_cmpd001","dataset":"ADMET","endpoint":"hERG","compound_id":"CMPD-001","model":"TDC hERG / LightGBM v1.2","text":"Predicted hERG liability: POSITIVE for CMPD-001 with probability 0.81. Model: LightGBM (TDC hERG baseline). Rationale: aromatic cationic features; cLogP moderate."}
{"id":"ames_pred_cmpd001","dataset":"ADMET","endpoint":"Ames","compound_id":"CMPD-001","model":"TDC Ames / XGBoost v1.1","text":"Predicted Ames mutagenicity: NEGATIVE for CMPD-001 (probability 0.72). No structural alerts in nitro-aromatics; heterocycles present but low risk."}
{"id":"lipophilicity_az_cmpd001","dataset":"AstraZeneca Lipophilicity","endpoint":"logD","compound_id":"CMPD-001","text":"Measured lipophilicity (AstraZeneca): logD7.4 = 2.1 (shake–flask). Method ID: AZ-SF-045. Interpretation: moderate permeability potential; solubility may be limiting if logS is low."}
{"id":"solubility_aqsoldb_cmpd001","dataset":"AqSolDB","endpoint":"logS","compound_id":"CMPD-001","text":"Predicted aqueous solubility: logS = -3.2 (mol/L). Model: GNN (AqSolDB). Guidance: borderline solubility; formulation may be required."}
{"id":"caco2_wang_cmpd001","dataset":"Caco2_Wang","endpoint":"Papp","compound_id":"CMPD-001","text":"Caco-2 apparent permeability (Wang): Papp = 19 × 10^-6 cm/s (predicted). Efflux ratio < 2 (suggests limited P-gp efflux)."}
{"id":"ld50_zhu_cmpd001","dataset":"LD50_Zhu","endpoint":"LD50","compound_id":"CMPD-001","text":"Predicted acute oral toxicity (mouse): LD50 = 580 mg/kg (Zhu). Category: moderate. Confidence: 0.63."}
{"id":"tox21_cmpd001_fxr","dataset":"Tox21","endpoint":"NR_FXR_antagonist","compound_id":"CMPD-001","text":"Tox21 screen (predicted): NR FXR antagonist = POSITIVE (score 0.63). Other NR panels: AR/ER negative at tested ranges."}
{"id":"clint_human_microsome_cmpd001","dataset":"ADMET","endpoint":"Clint","compound_id":"CMPD-001","text":"Human liver microsome clearance (predicted): Clint = 32 μL/min/mg protein. Suggests moderate hepatic clearance; consider DDI risk with CYP3A4."}
{"id":"cyp3a4_inhib_cmpd001","dataset":"ADMET","endpoint":"CYP3A4_inhibition","compound_id":"CMPD-001","text":"CYP3A4 inhibition (predicted): IC50 ≈ 3.4 μM. Classification: moderate inhibitor. Monitor potential interactions with 3A4 substrates."}
{"id":"assay_pik3cg_0002","dataset":"BindingDB","target":"PIK3CG","uniprot_id":"Q15858","assay_id":"BDB:123789","compound_id":"CMPD-003","smiles":"CCOc1ccc(Cl)cc1C(=O)N2CCN(CC2)C","text":"BindingDB assay [BDB:123789]. Target: PIK3CG (Q15858). Compound CMPD-003. IC50 = 140 nM (n=2). Assay: radiometric. Buffer: Tris. Cofactors: Mg2+."}
{"id":"herg_pred_cmpd003","dataset":"ADMET","endpoint":"hERG","compound_id":"CMPD-003","text":"Predicted hERG liability: NEGATIVE (probability 0.24) for CMPD-003. Comment: reduced basic center; lower risk."}
{"id":"ames_pred_cmpd003","dataset":"ADMET","endpoint":"Ames","compound_id":"CMPD-003","text":"Predicted Ames: NEGATIVE (probability 0.69). No strong mutagenic alerts detected."}
{"id":"solubility_aqsoldb_cmpd003","dataset":"AqSolDB","endpoint":"logS","compound_id":"CMPD-003","text":"Predicted aqueous solubility: logS = -2.4 (mol/L). Better than CMPD-001; compatible with standard oral formulation."}
{"id":"lipophilicity_az_cmpd003","dataset":"AstraZeneca Lipophilicity","endpoint":"logD","compound_id":"CMPD-003","text":"Measured logD7.4 = 1.7. Lower lipophilicity vs CMPD-001; may reduce hERG risk and improve solubility."}
{"id":"assay_herg_patch_cmpd001","dataset":"BindingDB","target":"KCNH2","uniprot_id":"Q12809","assay_id":"BDB:778899","compound_id":"CMPD-001","text":"hERG patch-clamp (BindingDB) [BDB:778899]. Inhibition at 1 μM = 46%. Estimated IC50 ≈ 1.6 μM. Temperature: 35 °C. Cells: HEK293."}
{"id":"clinTox_cmpd001","dataset":"ClinTox","endpoint":"clinical_toxicity_risk","compound_id":"CMPD-001","text":"ClinTox risk category: LOW (score 0.18). No historical clinical toxicity signals associated with scaffold family."}
{"id":"tox21_cmpd003_ar","dataset":"Tox21","endpoint":"NR_AR_antagonist","compound_id":"CMPD-003","text":"Tox21 NR AR antagonist: NEGATIVE (score 0.22). Panel summary favors a clean NR profile at tested concentrations."}
{"id":"caco2_wang_cmpd003","dataset":"Caco2_Wang","endpoint":"Papp","compound_id":"CMPD-003","text":"Caco-2 Papp (predicted): 14 × 10^-6 cm/s. Efflux ratio ~1.4. Suggests adequate absorption with low efflux."}
{"id":"pk_summary_cmpd001","dataset":"ADMET","endpoint":"PK_summary","compound_id":"CMPD-001","text":"PK summary (predicted): moderate clearance, moderate permeability, borderline solubility. hERG POSITIVE flag (0.81). Ames NEGATIVE. Consider solubility enhancement; monitor QT risk."}
